CN1322874A

CN1322874A - Aggregation-preventing wide-spectrum nanometer antibiotic silver yarn and its industrial production process

Info

Publication number: CN1322874A
Application number: CN 01115422
Authority: CN
Inventors: 朱红军
Original assignee: Individual
Current assignee: Individual
Priority date: 2001-04-25
Filing date: 2001-04-25
Publication date: 2001-11-21
Anticipated expiration: 2021-04-25
Also published as: CN1183285C

Abstract

Superfine silver grains of 1-100 nm size are attached to yarn of animal or plant fabric material, and the superfine silver grains are coated by one 2-8 nm thick silver oxide layer. The nanometer silver yarn produced via aggregation preventing process has extremely strong and wide-spectrum antibiotic capacity and no toxicity, irritation, allergic reaction and drug resistance. It may be used in weaving various antibiotic fabric for medical and health purpose.

Description

Aggregation-preventing broad-spectrum antibacterial nano-silver yarn and industrialized manufacturing process

The invention relates to a manufacturing process of an antibacterial yarn material, in particular to an anti-aggregation broad-spectrum antibacterial nano silver yarn and an industrialized manufacturing process.

As is known, nanotechnology is a new subject of research and development by using substances with particle sizes of 1-100 nanometers, is one of three major technologies for economic development in the 21 st century, and is also a new technology which is most likely to generate breakthrough achievement. The countries in the world compete for huge investment, and the technology integrates the elegance of developing the nanotechnology and the application thereof, and the research institutions from the upper central level to the lower level to the colleges and universities and grass-roots in China have great investment in the development trend of the nanotechnology, and especially the application and industrialization of the nanotechnology are the important factors for the research and development in China.

Many examples of silver antibacterial are disclosed in the prior art, for example, in Japanese patent No. Sho 54-151669, there is disclosed a bactericidal cloth obtained by treating a yarn with a resin solution containing a compound of copper and silver (average particle diameter of 6 μm) alone or in combination, uniformly coating the solution on the surface of the yarn, and then weaving the yarn into a bactericidal cloth, which can be used as a lining of rubber boots, canvas shoes and socks.

In the report of "processing technology" vol.17 No.7 in Japan, the acrylic fiber is treated with copper and sulfide to obtain an acrylic fiber-copper sulfide composite, which has bacteriostatic ability on staphylococcus aureus, escherichia coli, bacillus subtilis and dermatophytes.

In Chinese invention patent CN-87100231A, entitled "antibacterial deodorant fiber yarn and manufacturing method", the disclosure date is: 18.11.1987, an antibacterial yarn is disclosed, which is prepared by carrying out composite crosslinking on acrylic yarn with copper and alkaline green-4 in sequence, and the product has antibacterial function on 10 strains such as staphylococcus aureus, MRSA, staphylococcus albus, candida albicans and the like, and can be used as antibacterial and deodorant underwear, socks, insoles and work clothes in the medical industry and the food industry.

An antibacterial cloth for preventing mastitis in a cow is disclosed in Japanese patent laid-open No. Hei 3-136649, application date "24/10 in 1989. The silver ion and polyacrylonitrile are compounded in a coordination bond form, the product has an inhibiting effect on 6 strains such as streptococcus, staphylococcus and the like, and can be used as an antibacterial wiper for wiping the mammilla of a cow to prevent mastitis of the cow.

However, none of the above documents or reports relate to the use of nano silver and a suitable carrier as an antibacterial material.

The above products all have antibacterial effects, but the antibacterial spectrum is not wide, the effects are not obvious, and the products are completely different from the invention.

One of the purposes of the invention is to provide a broad-spectrum antibacterial nano-silver yarn.

Another object of the present invention is to provide a technique for preventing aggregation between ultrafine silver particles having a very high activity.

The invention also aims to provide an industrialized manufacturing process of the anti-aggregation broad-spectrum antibacterial nano-silver yarn.

These and other objects of the present invention will be further elucidated by the following detailed description and description.

In the invention, the aggregation-preventing broad-spectrum antibacterial nano silver yarn is characterized in that ultrafine silver particles with the particle size of 1-100 nanometers are firmly attached among and on fiber elements of yarn made of natural animal and plant textile materials, the surface layer of the ultrafine silver particles is silver oxide with the particle size of 2-8 nanometers, the core of the ultrafine silver particles is elemental silver, and the content of the silver is 0.1-50 mg/g based on the weight of the yarn. The natural animal and plant textile material is conventional textile and papermaking pulp, can be fiber pulp of cotton, wool, hemp, silk, bamboo, wood and paper and chemical fiber, can be one of the pulp, and can also be a mixed thread of the product.

The industrialized production process of the aggregation-preventing broad-spectrum antibacterial nano-silver yarn comprises the step of preventing aggregation among silver ultrafine particles with extremely strong activity.

Further, the industrialization manufacturing process of the aggregation-preventing broad-spectrum antibacterial nano silver yarn comprises the steps of preparing a medicament, spraying the medicament on the yarn, continuously adding a dispersing agent into a reaction kettle, reacting, cleaning, centrifugally dewatering, drying and the like, wherein all the steps are carried out under a ventilation condition, and the medicament preparation formula (calculated by 10 kilograms of yarns) is as follows:

adding a preparation A, 0.005-0.3M of silver nitrate, 0.002-0.15M of ammonia water and 0.01-0.2M of sodium hydroxide, and adding water until the total volume is 50 liters;

adding a preparation B, 0.1-5M of glucose or ascorbic acid, 0.02-0.2M of nitric acid and 2-10M of ethanol, and adding water until the total volume is 5 liters;

when in use, 10 parts by volume of the preparation agent A and 1 part by volume of the preparation agent B are uniformly mixed and then are placed for 10 to 40 minutes for later use. Spraying the chemical onto the yarn, reacting in a reactor, and adding dispersant continuously until the product is brown yellow.

The aggregation-preventing broad-spectrum antibacterial nano-silver yarn can be made into antibacterial medical materials and antibacterial textiles, and can be used as a antibacterial material in the fields of field, battlefield, disaster area, environmental protection, traffic, aviation, aerospace, public places and the like.

Furthermore, the product of the invention can be used as a medical (external) material for treating burns and scalds, a material for treating skin infection and superficial skin fungal infection of trauma patients and preventing and treating incision infection after surgical incision operation, and also can be used as a daily life health care product, has broad-spectrum antibacterial property, long-acting property, capability of killing drug-resistant pathogenic bacteria, stronger hydrophily-water sterilizing capability, washing resistance, nontoxicity, nonirritant, no allergy, no drug resistance and other excellent performances. Can be used for treating skin infection and dermatophyte infection of trauma patients and surgical incision infection. Especially for the field prevention and treatment of trauma infection under adverse environmental conditions such as field operation, war wound of sea water polluted wound, flood, fire, earthquake, etc. More importantly, the product of the invention can be used for treating intractable infection such as intractable bedsore infection, burn and scald wound infection and the like, and opens up an industrialization example of the application of nanotechnology in the field of human body infection resistance.

The technology of the present invention can prevent the aggregation of newly generated silver ultrafine particles with nanometer particle size and strong surface activity, thereby preventing the generation of silver particles with larger particle size. The production is successful after the laboratory production and pilot plant test, the production operation and the productquality are stable, and the annual output value is estimated to reach more than 10 hundred million yuan.

The invention will be further described by means of the figures and flow charts.

FIG. 1 is a photograph of a silver sample not using this technique observed under a microscope.

FIG. 2 is a photograph of a silver sample not using this technique observed under a microscope.

FIG. 3 is a photograph of a silver sample not using this technique observed under a microscope.

FIG. 4 is a photograph showing the microscopic observation of a silver sample using the technique of the present invention

FIG. 5 is a process flow diagram of the present invention.

The invention relates to an aggregation-preventing broad-spectrum antibacterial nano silver yarn (hereinafter referred to as PNST) belonging to the nano material science, wherein inorganic nano micro-particles are dispersed on a natural organic matrixA particulate organic-inorganic nanocomposite. The carrier of the PNST is selected from a plurality of materials which can be taken as the carrier and are mastered by people, and yarns are taken as the carrier of the PNST. The organic carrier is yarn, the inorganic nano is ultrafine silver with the particle size of 1-100 nanometers, and the inorganic nano can be used as a functional material and particularly applied to the field of human body infection resistance. As for the definition of the nano material, besides the particle size of 1-100 nm, the nano material also needs to have specific performance which is far superior to that of the homogeneous material with macroscopic size in certain important performance. That is, if the particle size is 1-100 nm and the specific property is required, the particle size is not limited to be 1-100 nm, otherwise the particle size cannot be defined as a nano material. The ultrafine nanoparticles having a particle size of 1 to 100 nm have a very large specific surface area and are inversely proportional to the particle size, as compared with homogeneous macro-particles. For example: 1 g of copper with a particle size of 5 nm and a specific surface of 130 m²Per gram; the particle diameter is 2 nanometers, and the specific surface area is 330 meters²Per gram; at the same time, in addition to surface effect, i.e. volume percentage distributed on the surface of particle, when the particle size is 5 nm, its surface volume percentage is 50%, and when the particle size is 2 nm, its surface volume percentage is 80%, at this time, the atomic number in the surface layer can be quickly increased due to reduction of particle size, so that its original coordination is insufficient, unsaturated bond is exposed and increased, and surface energy of atom is raised, so that the chemical activity of these nano-grade ultramicro particles is very strong, so that at the moment when these ultramicro particles are just produced, they can be inevitably collided with each other, so that two or several of these collided ultramicro particles can be aggregated, so that the large particles whose particle size is greater than N, No and Noo times of original particle size can be produced, and even the particles whose macro-size is formed due to aggregation action, and their correspondent chemical activityLow, the properties of the nanomaterial will eventually be lost. It is understood that the present invention achieves the effect of preventing the aggregation of newly formed ultrafine particles by appropriate chemical and physical means. The aggregation prevention technology is important for the success of a method for manufacturing 1-100 nm ultrafine particles mainly by a chemical method and secondarily bya physical method. To confirm the efficacy of the anti-agglomeration technique, we performed electronic visualization of silver samples with and without the techniqueThe effect of the micromirror detection and photography is obvious, please refer to fig. 1, fig. 2, fig. 3 and fig. 4.

FIGS. 1, 2 and 3 show a product without the agglomeration preventing technique, in which the size of the deposit of spherical particles is much larger than that of spherical particles.

FIG. 4 is an electron micrograph of PNST using the anti-agglomeration technique, clearly showing that the majority of the nanoparticles on PNST have a particle size of 5-100 nm and are distributed uniformly and regularly, and a stripe-shaped ridge is formed in the middle of the photograph, but it can be clearly seen that the particles are not spherical nanoparticles stacked, and may be minute ridges on the surface of cilia in the carrier. In addition, in order to determine the composition of the ultrafine particles on the PNST, the surface layer of the spherical ultrafine particles is silver oxide with the thickness of 2-8 nanometers, the core of the spherical ultrafine particles is element silver, and the silver content of the nano silver on the PNST is determined to be 0.1-50 mg/g by a method of United states pharmacopoeia and British pharmacopoeia.

The function and detection test of the PNST are as follows:

the PNST of the invention is measured by an electron microscope and a photoelectron spectrometer, and most of the silver particles of the PNST are ultrafine particles with the particle size of 5-100 nanometers and consist of Ag₂O + Ag, the surface layer of the particles is Ag₂O, which is a silver particle having a core of elemental silver and can be clearly defined as a nano-sized particle, is confirmed by the following tests as to whether or not it has excellent specific properties, and the test results are shown in tables 1 and 2.

Table 1 shows the results of the laboratory tests of microorganisms in the general medical testing center of the people's liberation army of China.

Table 2 is a test conducted in the bacterial laboratory of Huashan Hospital, Shanghai medical university.

The antibacterial mechanism of the PNST is a classical antibacterial mechanism:

from the above it can be seen that PNST is through the most classical antibacterial mechanism,the enzyme 2SAg and H are produced by substituting-SH group in enzyme living in bacteria with-SAg to inactivate the enzyme and thereby kill germs₂O，No secondary pathogenic factors exist.

The results of the experiments shown in tables 1 and 2 show that the PNST of the present invention has the following excellent specific functions.

1. Broad spectrum of antibacterial:

the strains shown in tables 1 and 2 include gram-positive bacteria, gram-negative bacteria, fungi, spores and anaerobic bacteria, and the broad antimicrobial spectrum is very rare in the existing antimicrobial drugs. The number of strains counted in the strain removal repeat referred to in tables 1 and 2 was 38, and most of the strains were isolated from the secretions of the drug-resistant clinical patients.

2. Long-lasting property:

table 1, 50 and 20 washes shown in table 2 are 50 and 20 rinses of PNST with soap and hand scrub water each time. The 100 times of washing is 100 times ofscrubbing with clean water each time, and the antibacterial performance of the washed PNST is not obviously reduced.

3. Comparison of bacteriostatic effects of PNST and 8 antibacterial agents on pathogenic bacteria:

table 1 shows that 8 antibacterial drugs PNST (28) of the invention, erythromycin (7), ampicillin (4), cefuroxime (4), ceftazidime (15), oxacillin (2), gentamicin (6) and ciprofloxacin (14) are subjected to in vitro bacteriostasis tests simultaneously. The number in parentheses after the name of each drug is the number of bacteria that the drug is able to inhibit. It can be seen that PNST is much superior to the 8 antibacterial agents in terms of resistance to drug-resistant pathogenic bacteria. This may be desirable to break the current growth in bacterial resistance, which has made the development of antibiotics unable to keep up with the embarrassing situation of bacterial resistance growth. It is anticipated from the above that the PNST of the present invention will likely become an alternative drug to antibiotics.

4. The hydrophilicity is stronger when meeting water sterilization

From Table 1 and Table 2, it can be seen that the bacteriostatic ability of PNST has no obvious decline after multiple rubbing, and the main mechanism is Ag on PNST₂O has slow-release property, generally inIn the presence of water, even the moisture on the body surface or the water amount in the wet state when applied is sufficient to make Ag⁺When [ Ag]is released⁺]Up to 0, n-5ppm 10^-6]Can reach Ag⁺Dynamic equilibrium of (1), and Ag⁺Has a minimum inhibitory concentration of 2 × 10^-11M, the antibacterial mechanism and the absence of secondary pathogenic factors during the antibacterial process for pnst. have been elucidated in the section "antibacterial mechanism" above. In addition, the following experiment is carried out, 0.5 g of PNST is taken and soaked in 500 ml of water every day, the water is changed once every day, and the bacteriostatic ability of the PNST yarn does not obviously decrease after 45 days. Therefore, the needles and textiles made of PNST as the raw material have stronger antibacterial power when meeting water. This is very beneficial for current burn and scald moistening therapy. The clinical verification of the medical inspection center of the whole military of the Chinese people liberation army shows that the curative effect is good, and the field treatment research on the war injury caused by seawater pollution in the fourth military medical university of the Chinese people liberation army and the subsidiary Cijing hospital thereof proves that the PNST has good curative effect and actually belongs to the advanced level in the world, so the PNST is specially used for the treatment of the war injury caused by the seawater pollutionIs particularly suitable for preventing and treating wound infection under adverse environmental conditions such as field operation, battlefield and the like.

5. Pharmacokinetic Studies

Through the national Beijing New drug safety evaluation research center and the national people liberation military medical inspection center Pharmacology department, mice, guinea pigs and white big-ear rabbits are used as test objects. PNST is used as an experimental medicine, and is subjected to skin acute toxicity test, irritation test, allergy test and mouse acute toxicity test, maximum tolerance amount determination test and accumulative toxicity test, particularly, the PNST amount is 925 mg/kg of the maximum tolerance amount after single gastric lavage administration of mice (9 mice) and is equivalent to 4625 times of the clinical dose of human beings, toxic symptoms and death are not found after continuous observation for 14 days after administration, and the growth condition is better. Thus, PNST was found to be non-toxic, non-irritating, non-allergic, and non-drug resistant.

6. Comparison of in vitro bacteriostasis of PNST with silver microparticles of homogeneous macroscopic particle size

The PNST yarns of the invention are respectively placed in small circles with the diameter of 6 mm, the silver content of the PNST yarns is only 10% of that of the PNST yarns^-3～10^-4. However, on an agar MH plate for in vitro bacteriostasis, the bacteriostasis ring of the agar MH plate is 12-20 mm, and the bacteriostasis ring of the agar MH plate is not. It can be seen that macroscopically sized, homogenous silver particles are not comparable to PNST in terms of bacteriostatic ability.

In conclusion, the functions of the PNST disclosed by the invention comprise broad-spectrum antibacterial property, long-acting property, stronger antibacterial ability to pathogenic bacteria with drug resistance, stronger hydrophilic-water bactericidal ability, no toxicity (including no accumulative toxicity), no irritation, no allergy, no drug resistance and the like, which are far superior to the current commonly-used antibacterial drugs and are also far superior to the macroscopic homogeneous silver yarns, so that the silver particles on the PNST disclosed by the invention not only meet the requirement of the particle size of 1-100 nanometers, but also have special superior antibacterial performance. The silver particles on the PNST of the present invention can be defined without any problem as nano silver.

The essence of PNST is that the aggregation preventing technology of the present invention is adopted to produce silver (Ag) with ultrafine particles having a particle size of 1 to 100 nm uniformly and firmly attached to the yarn₂O + Ag) particles to obtain PNST.

The process flow of the invention is as follows: putting theyarns into a sprayer, spraying a preparation agent A and a preparation agent B into a reaction kettle in the sprayer to react, putting a dispersing agent into the reaction kettle while reacting, cleaning the yarns attached with the nano-silver micro-powder by a cleaning machine, centrifugally dewatering by a dewatering machine, and drying by a drying machine to obtain the finished product.

In the invention, the yarn, the auxiliary agent and the additive can be purchased from the market, the dispersing agent is the anti-agglomeration agent commonly used in the industry, the specific variety can be found from various conventional manuals, for example, isopropanol, sodium dodecyl benzene sulfonate, sodium succinate sulfonate, colloidal palladium or colloidal palladium, OP-10, trialkyl phosphates such as tributyl phosphate, trioctyl phosphate, triisopentyl phosphate and triisooctyl thiophosphate can be used, and refer to the statement on page 49-57 of silicate report on 2 in 1986, Shen 'preparation of fine ceramic micro powder'.

In the invention, the used devices are specially designed and manufactured, and the yarn treatment adopts the anti-gathering technology.

The present invention is further illustrated by the following specific examples, which are intended to be illustrative only and not to limit the scope of the invention.

In the present invention, unless otherwise specified, all parts and amounts are by weight based on total weight and "M" is the molar concentration.

Example 1

The liquid medicine is prepared according to the following amount (measured by 10 kilograms of yarns)

Formulation A, AgNO₃0.3M,NH₃·H₂O 0.15M,NaOH 0.1M,

Adding deionized water to a total volume of 50 liters;

compounding agent B, glucose 4M, HNO₃0.1M, boiling for 1-5 minutes, cooling, and adding ethanol to obtain 10M solution with volume of 5 liters.

Mixing 10 parts of the preparation agent A and 1 part of the preparation agent B (V/V) uniformly, standing for 10-40 minutes for spraying and soaking, putting 10 kilograms of yarns, spraying and soaking to uniformly mix liquid medicine and the yarns, putting the yarns into a reaction kettle for chemical and physical treatment, continuously adding a dispersing agent-OP-10 (under ventilation conditions) until the yarns are brown yellow, and then cleaning, centrifugally dewatering and drying to obtain the aggregation-preventing broad-spectrum antibacterial nano-silver yarn finished product.

Example 2

Formulation A, AgNO₃0.3M,NH₃·H₂0.15M of O, 0.07M of NaOH and distilled water are added until the total volume is 50 liters;

formulation B, ascorbic acid 3M, HNO₃0.1M, boiling for 1-5 minutes, cooling, and adding ethanol to obtain 10M solution with volume of 5 liters.

Mixing 10 parts of the preparation A and 1 part of the preparation B (V/V) uniformly, standing for 10-40 minutes for spraying, and adding 10 kilograms of degreased all-cotton yarn. After spraying, the liquid medicine and the yarn are uniformly mixed, the mixture enters a reaction kettle for chemical and physical treatment, sodium dodecyl benzene sulfonate is added as a dispersing agent (under ventilation) until the yarn is brownish yellow, and then the finished product of the aggregation-preventing broad-spectrum antibacterial nano-silver yarn is obtained after cleaning, centrifugal dehydration and drying.

Example 3

Formulation A, AgNO₃0.008M,NH₃·H₂O0.05M, NaOH 0.05M, and distilled water to a total volume of 50 liters;

compounding agent B, ascorbic acid 0.10M, HNO₃0.15, boiling for 1-5 minutes, cooling, and adding ethanol to obtain 5M solution with volume of 5 liters.

Example 4

Formulation A, AgNO₃0.1M,NH₃·H₂O0.08M, NaOH 0.05M, and distilled water to a total volume of 50 liters;

compounding agent B, ascorbic acid 0.12M, HNO₃0.11M, boiling for 1-5 minutes, cooling, and adding ethanol to obtain 6M solution with volume of 5 liters.

The aggregation-preventing broad-spectrum antibacterial nano-silver yarn is mainly used for developing medical functional products and antibacterial health-care needles and textiles, and can be used as a medical functional dressing for external antibacterial treatment of body surface wounds after clinical verification, so that the aggregation-preventing broad-spectrum antibacterial nano-silver yarn becomes a preferred product for replacing antibacterial drugs and neutral dressings. Meanwhile, the fiber yarn also relates to the medical health industry and the needle and textile industry, such as various medical functional fiber yarns and needles and textiles used in the medical health industry, and antibacterial and health-care fiber yarns, needles and textiles used in various industries and fields.

TABLE 1

Bacteriostasis results of PNST and 8 antibacterial drugs

MIC method drug sensitivity result of antibacterial drugs with bacteriostatic diameter (mm) of PNST and control group

Bacterial name source erythromycin benzazole ampicillin cefcephalosporin cefazepindol C negative in unwashed washing

50 times 100 controls of penicillin azoline furazoline Oxime Talidomycin Asafloxacin Staphylococcus aureus ATCC 25923181515724S S S S S S S Escherichia coli ATCC 25922131312710S S S S S Pseudomonas aeruginosa ATCC 2785312121276S Clostridium perfringens CMCC (B) 6460610 Staphylococcus aureus (MRSA) secretion 17151576R R R R R R R R secretion 18151676R R R R R Streptococcus pyogenes secretion 98876S S S S S S S S S Neisseria gonorrhoeae secretion 101010731S S S S S S S S Escherichia coli secretion 17141476R R R R R R Enterobacter cloacae 988711R R R R R R secretion 14121376R R R R R R R Pseudomonas aeruginosa secretion 15151576R R R secretion R R R R stenotrophomonas maltophilia secretion 14131476R R R S S Acinetobacter baumannii secretion 131212719R R R S S Klebsiella pneumoniae secretion 15141476R R S R S Serratia marcescens secretion 16131476R R R R S Klebsiella farinacea secretion 11101176R R R R R R R R Klebsiella farinacea secretion 15131376R R S hydrophilic Aeromonas species secretion 131113716R R R S S Aeromonas sobromyces secretion 141212717R I S S Vibrio vulnificus secretion 17151576R R S S Proteus mirabilis secretion 11101079R R R S R R R R R Proteus secretion 1191176R R R R R R Proteus pennisatus secretion 1091076R R R R S Proteus farinaceus secretion R ri S R S candida albicans secretion 21202076 candida tropicalis secretion 18171876 candida parapsilosis secretion 20192076 torulopsis glabrata secretion 27262676 note: s: sensitivity I: an intermediate R: drug resistance

TABLE 2

Strain blank AB fabric PNST

20 times of no-washing of fabrics, 20 times of high-pressure no-washing and 20 times of high-pressure no-washing of 50 times of pseudomonas aeruginosa, 15131616 staphylococcus aureus, 15171515 escherichia coli, 13141815 MRSA, 14141715 bacillus cereus, 1113131515 vibrio vulnificus, 16161617 candida albicans, 21 11111111B group hemolytic streptococcus, 11111211 pseudomonas maltophilia, 12121514 nitrate negative bacillus, 14141315 salmonella paratyphi, 12, 12141914 salmonella alimentarius, 14141514 citrobacter, 14141513 pneumobacillus, 13131713 bacillus subtilis, 12121212 rhizogenes, 1012121212 alcaligenes faecalis, 14121616 pseudomonas stutzeri 12121413 Enterobacter cloacae-13131313 gonococcus-11111111

The results show that PNSM has inhibition effect on 20 strains of bacteria, and on bacteria which are easy to generate drug resistance, such as staphylococcus aureus drug-resistant strains (MRSA), pseudomonas aeruginosa, pseudomonas maltophilia, nitrate negative bacillus and the like, the inhibition effect on the bacteria is not obviously affected after high pressure and washing for 20 times and 50 times, and the bacteria cannot be inhibited after the AB fabric is washed for 20 times, so that the inhibition range of PNSM is wider than that of the AB fabric, and the inhibition effect cannot be affected by washing.

Claims

1. An aggregation-preventing broad-spectrum antibacterial nano silver yarn is characterized in that ultrafine silver particles with the particle size of 1-100 nm are firmly attached among and on fiber elements of yarns made of natural animal and plant textile materials, the surface layer of the ultrafine silver particles is silver oxide with the particle size of 2-8 nm, and the core of the ultrafine silver particles is elemental silver.

2. The aggregation-preventing broad-spectrum antibacterial nano-silver yarn as claimed in claim 1, wherein the ultra-fine silver particles are firmly attached to the fiber elements and fibers of the yarn made of natural animal and plant textile materials, and the silver content is 0.1 to 50 mg/g based on the weight of the yarn.

3. The anti-agglomeration broad-spectrum antibacterial nano-silver yarn according to claim 1, wherein the natural animal and plant textile material is conventional textile and paper pulp, and can be fiber pulp of cotton, wool, hemp, silk, bamboo, wood and paper and chemical fiber, either alone or in combination.

4. The industrial process for producing aggregation-preventing broad-spectrum antibacterial nano-silver yarn according to claims 1 to 3, comprising a step of preventing aggregation between silver ultrafine particles having extremely strong activity during the production process.

5. The industrial process of preparing the aggregation preventing broad spectrum antibiotic nano silver yarn as claimed in claim 4 includes compounding chemical, spraying chemical to the yarn, adding dispersant continuously into the reactor for reaction, washing, centrifugal dewatering, drying and other steps.

6. The industrialized production process of the aggregation-preventing broad-spectrum antibacterial nano-silver yarn as claimed in claim 4, characterized in that the preparation formula of the medicament is (based on 10 kg of yarn):

when in use, 10 parts by volume of the preparation agent A and 1 part by volume of the preparation agent B are uniformly mixed and then are placed for 10 to 40 minutes for later use.

7. The industrial process of claim 4, wherein the chemical is sprayed onto the yarn, the yarn is placed into a reaction kettle for reaction, and the dispersing agent is continuously added until the product is brown yellow.

8. The use of the anti-aggregation broad-spectrum antibacterial nano-silver yarn according to claim 1, characterized in that the yarn can be made into antibacterial medical materials and antibacterial textiles.

9. The use of the anti-aggregation broad-spectrum antibacterial nano-silver yarn according to claim 1, which is characterized in that the yarn can be used as a bactericidal material in the fields of field, battlefield, disaster area, environmental protection, transportation, aviation, aerospace, public place and the like.